[Hydergin therapy of cerebrovascular insufficiency in patients requiring digitalis. Results of a double-blind study (author's transl)].
In a controlled double-blind trial in 80 patients with cerebrovascular and cardiac insufficiency the differentiated effect of a combination therapy with cardiac glycosides and Hydergin were studied both with regard to parameters of cerebral organic and cardiac performance. Two randomized collectives of patients with an average age of 63 years were compared with each other for this purpose. They received either acetyldigoxin (0.4 mg/day) alone or in combination with Hydergin (3 mg/day). Duration of treatment was 8 weeks altogether. The single treatment with the cardiac glycoside alone does not lead to a satisfactory improvement in the symptoms of cerebral attacks. The results presented of this study support the necessity in these patients of an internist basic therapy in combination with a preparation like Hydergin acting favorably on cerebral metabolism.
D000113:Acetyldigoxins / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000150:complications / Q000188:drug therapy*; D004077:Digoxin / Q000031:analogs & derivatives*; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000113:Acetyldigoxins; D004088:Dihydroergotoxine; D004077:Digoxin
Behandlung der zerebrovaskulären Insuffizienz. Einsatz von Hydergin bei digitalisbedürftigen Patienten - Ergebnisse einer Doppelblindstudie.